Brought to you by 
King gets US, Canadian rights to Avinza from Ligand
09 Dec 2020
Executive Summary
Small-molecule developer Ligand has licensed King Pharmaceuticals (markets drugs for hospital/acute care markets and cardiovascular, metabolic, and neurological diseases) US and Canadian rights to the chronic pain drug Avinza (morphine sulfate). King signed a contract sales agreement to promote the product during the transition period until the deal closes.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
King gets US, Canadian rights to Avinza from Ligand
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice